Sandoz Scores European Approval for Biosimilar Rituximab
The European Commission approved Rixathon for use in all indications of its reference medicine, MabThera.
Sandoz, a division of Novartis, announced on June 19, 2017 that the European Commission (EC) has approved Rixathon (biosimilar rituximab) for use in Europe. Rixathon is approved for use in all indications of the reference medicine, MabThera, the company said in a press release.
In a statement, Carol Lynch, global head of Biopharmaceuticals at Sandoz called the approval a “big win for patients in Europe with blood cancers or immunological diseases.” Rixathon is approved for non-Hodgkin's lymphoma (follicular lymphoma and diffuse large B-cell lymphoma) and chronic lymphocytic leukemia, as well as immunological diseases such as rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.
The EC approval was based on a comprehensive development program generating analytical, preclinical, and clinical-including pharmacokinetic/pharmacodynamics-data, the company said. The program demonstrated Rixathon matches its reference medicine in terms of safety, efficacy, and quality.
Source: Novartis
Tokyo University of Science Research Team Explores Improved Delivery of Antisense Oligonucleotides
April 18th 2025Using cholesterol-modified oligonucleotides, the research team aims to improve the delivery of antisense nucleotide-based therapies for treating neurodegenerative diseases and brain cancers.
British Patient Capital Invests £10 Million in Maxion Therapeutics, Part of Series A Financing Round
March 27th 2025The £10 million (US$13 million) investment is part of a larger £58 million (US$75 million) Series A financing round to be used for the development of Maxion Therapeutics’ preclinical lead program for treating inflammatory diseases.
